With the FDA's decision date on the approval of Xiaflex for the
treatment of Peyronie's disease looming (September 6), considerable
attention has come to Auxilium Pharmaceuticals (AUXL)
in recent weeks. While the FDA's decision is absolutely a significant
event for the company, investors shouldn't overlook the company's
challenges in its existing specialty pharmaceuticals business, as well
as the efforts that will have to go into making Xiaflex a winner in
Peyronie's assuming approval.
Read more here:
Approval In Peyronie's Only Part Of The Auxilium Story
No comments:
Post a Comment